Status:
COMPLETED
Evaluate the Pharmacokinetics of Quetiapine Fumarate in Chinese Schizophrenic Patients
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
The primary objective of the study is to evaluate the pharmacokinetics of XR quetiapine fumarate(300mg,600mg,and 800mg once-daily) in Chinese schizophrenic patients .
Eligibility Criteria
Inclusion
- Men and women aged 18 through 60 years inclusive
- Schizophrenia diagnosis
- Body Mass Index (BMI) 20-27 kg/m2 (inclusive)
- Provision of written informed consent before initiation of any study
Exclusion
- AIDS \& hepatitis B
- History of seizure disorder
- History of episodic,idiopathic orthostatic hypotension
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT00919607
Start Date
June 1 2009
End Date
March 1 2010
Last Update
March 26 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Beijing, Beijing Municipality, China